Posterior Cortical Atrophy: Characteristics From a Clinical Data Registry. by Olds, Jennifer J et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Neurology Faculty Papers Department of Neurology 
6-3-2020 
Posterior Cortical Atrophy: Characteristics From a Clinical Data 
Registry. 
Jennifer J Olds 
Department of Ophthalmology, Keesler Air Force Base, Biloxi, MS, United States 
William L Hills 
Department of Neurology Ophthalmology, Casey Eye Institute, Oregon Health Science University, Portland, 
OR, United States 
Judith Warner 
Department of Ophthalmology Neurology, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, 
United States 
Julie Falardeau 
Department of Ophthalmology, Casey Eye Institute, Oregon Health Science University, Portland, OR, United 
States 
Lori Haase Alasantro 
Department of Neuroscience, The Neurology Center of Southern California, University of California San 
Diego School of Medicine, Carlsbad, CA, United States 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp 
 Part of the Neurology Commons 
Let us know how access to this document benefits you 
Rec mmended Citation 
Olds, Jennifer J; Hills, William L; Warner, Judith; Falardeau, Julie; Alasantro, Lori Haase; Moster, 
Mark L; Egan, Robert A; Cornblath, Wayne T; Lee, Andrew G; Frishberg, Benjamin M; Turbin, 
Roger E; Katz, David M; Charley, John A; and Pelak, Victoria S, "Posterior Cortical Atrophy: 
Characteristics From a Clinical Data Registry." (2020). Department of Neurology Faculty Papers. 
Paper 217. 
https://jdc.jefferson.edu/neurologyfp/217 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson 
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Jennifer J Olds, William L Hills, Judith Warner, Julie Falardeau, Lori Haase Alasantro, Mark L Moster, 
Robert A Egan, Wayne T Cornblath, Andrew G Lee, Benjamin M Frishberg, Roger E Turbin, David M Katz, 
John A Charley, and Victoria S Pelak 
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/neurologyfp/217 
BRIEF RESEARCH REPORT
published: 03 June 2020
doi: 10.3389/fneur.2020.00358
Frontiers in Neurology | www.frontiersin.org 1 June 2020 | Volume 11 | Article 358
Edited by:
Janine Leah Johnston,
University of Manitoba, Canada
Reviewed by:
Michael S. Vaphiades,
University of Alabama at Birmingham,
United States
Keir Xin Xian Yong,
University College London,
United Kingdom
*Correspondence:
Victoria S. Pelak
victoria.pelak@cuanschutz.edu
Specialty section:
This article was submitted to
Neuro-Ophthalmology,
a section of the journal
Frontiers in Neurology
Received: 14 February 2020
Accepted: 14 April 2020
Published: 03 June 2020
Citation:
Olds JJ, Hills WL, Warner J,
Falardeau J, Alasantro LH,
Moster ML, Egan RA, Cornblath WT,
Lee AG, Frishberg BM, Turbin RE,
Katz DM, Charley JA and Pelak VS
(2020) Posterior Cortical Atrophy:
Characteristics From a Clinical Data
Registry. Front. Neurol. 11:358.
doi: 10.3389/fneur.2020.00358
Posterior Cortical Atrophy:
Characteristics From a Clinical Data
Registry
Jennifer J. Olds 1, William L. Hills 2, Judith Warner 3, Julie Falardeau 4,
Lori Haase Alasantro 5, Mark L. Moster 6, Robert A. Egan 7, Wayne T. Cornblath 8,
Andrew G. Lee 9, Benjamin M. Frishberg 5, Roger E. Turbin 10, David M. Katz 11,
John A. Charley 12 and Victoria S. Pelak 13*
1Department of Ophthalmology, Keesler Air Force Base, Biloxi, MS, United States, 2Department of Neurology &
Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, United States, 3Department of
Ophthalmology & Neurology, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, United States, 4Department of
Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, OR, United States, 5Department of
Neuroscience, The Neurology Center of Southern California, University of California San Diego School of Medicine, Carlsbad,
CA, United States, 6Department of Neurology and Ophthalmology, Wills Eye Hospital and Thomas Jefferson University,
Philadelphia, PA, United States, 7 Eye & Vascular Neurology, LLC, Carlton, OR, United States, 8Department of
Ophthalmology, Visual Sciences & Neurology, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, United States,
9Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, United States, 10Division of
Neuro-ophthalmology and Orbital Surgery, Rutgers New Jersey Medical School, Institute of Ophthalmology and Visual
Sciences, Newark, NJ, United States, 11 Bethesda Neurology, LLC, Department of Ophthalmology & Neurology, Howard
University Hospital, Georgetown University Hospital, Washington, DC, United States, 12 Retired Private Practice
Ophthalmologist, Pittsburgh, PA, United States, 13Department of Neurology & Ophthalmology, UCHealth Sue
Anschutz-Rodgers Eye Center and the Neurosciences Center, University of Colorado School of Medicine, Aurora, CO,
United States
Background: Posterior cortical atrophy (PCA) is a neurodegenerative syndrome that
presents with higher-order visual dysfunction with relative sparing of memory and
other cognitive domains, and it is most commonly associated with Alzheimer’s disease
pathology. There is a lack of data regarding the presentation of PCA to non-cognitive
specialists. Therefore, we collected clinical data from neuro-ophthalmologists regarding
the presentation of PCA to their practices and compared data to published cohorts and
a published survey of cognitive specialists.
Methods: Members of the North American Neuro-Ophthalmology Society Listserv
(NANOSnet) were invited to complete an online, retrospective, chart-review data-entry
survey regarding their patients with PCA, and REDCap was used for data collection.
Results: Data for 38 patients were entered by 12 neuro-ophthalmologists. Patient mean
age at presentation was 67.8 years, and 74% of patients were women. Difficulty reading
was reported at presentation by 91% of patients, and poor performance on color vision,
stereopsis, and visual field testing (performed reliably by 36/38 patients) were common
findings. Most patients who were treated were treated with donepezil and/or memantine.
Conclusions: Compared to published data from cognitive specialists, patients
presenting to neuro-ophthalmology with PCAwere more likely to be older and female and
have a reading complaint. Reliable visual field testing was the norm with homonymous
Olds et al. PCA: Neuro-Ophthalmology Registry
defects in the majority of patients. The neuro-ophthalmologist plays an important role in
diagnosing PCA in older adults with unexplained visual signs and symptoms, and future
studies of PCA should involve multiple specialists in order to advance our understanding
of PCA and develop effective treatments.
Keywords: posterior cortical atrophy, Benson’s syndrome, higher-order visual dysfunction, Alzheimer’s disease,
neuro-ophthalmology, patient registry
INTRODUCTION
Posterior cortical atrophy (PCA) is a progressive,
neurodegenerative syndrome that is characterized by higher-
order visual dysfunction with initial relative sparing of memory
and other cognitive functions (1). The prevalence of PCA
is unknown, and it is commonly considered an atypical
presentation of Alzheimer’s disease (AD) because most cases
at autopsy reveal AD pathology. Other pathologies found in
isolation or with Alzheimer’s pathology are α-synucleinopathy
consistent with Lewy body dementia, corticobasal degeneration,
prion disease, and non-specific pathologies (1). In 2017, formal
PCA diagnostic criteria were agreed upon by expert consensus
and published with the intention of creating a uniform definition
to be used in research settings (2). See Table 1 for a summary of
the criteria. Since the initial description by Benson et al. (3), PCA
patient characteristics have been described in numerous small
case series and case reports, and these reveal that ocular disease
is not the cause of visual symptoms in PCA and that the early
stages of the PCA syndrome are distinct from AD by the clinical
complaints, the type of cognitive and perceptual dysfunction
present, and the neuroimaging findings (2). Posterior cortical
atrophy typically progresses to a multicognitive domain
dementia, and the initial features that distinguish the syndrome
from typical AD, or typical Lewy body dementia, blur later in
the course (3). Other patients with PCA will have progressive
higher-order visual dysfunction with persistent relative sparing
of other cognitive domains over many years and even beyond a
decade (4).
Investigations of disorders that are relatively rare and/or
poorly recognized, such as PCA, face many challenges and
require collaboration across institutions for true progress to be
made in understanding clinical presentations, risk factors, and
pathophysiology, as well as for the development of treatments (5).
Many patients with PCA are diagnosed after significant delays
following onset of symptoms, and it is suspected that the early
age at onset and a prolonged search for ocular causes of visual
symptoms lead to the delay in diagnosis (1, 6).
The recent consensus classification criteria for PCA for
research purposes, set forth by an international, multidisciplinary
working party as noted (2), have accelerated the pace of
publications on PCA. Experts in the working party weremembers
of the Atypical Alzheimer’s Disease and Associated Disorders
Professional Interest Area (now called the Atypical AD PIA)
of the Alzheimer’s Association International Society to Advance
Alzheimer’s Research and Treatment (ISTAART). Criteria were
based on consensus following a survey-based questionnaire that
queried experts regarding their experience in the diagnosis and
TABLE 1 | Consensus research framework criteria for posterior cortical
atrophy (2).
Core Clinical
Features:
All three must
be present
• Insidious onset
• Gradual progression
• Prominent early disturbance of visual functions, other
posterior cognitive functions, or both
Core Cognitive
Features:
At least three must
be present as an
early or
presenting feature
Space perception deficit, simultanagnosia, object
perception deficit, constructional dyspraxia,
environmental agnosia, oculomotor apraxia, dressing
apraxia, optic ataxia, alexia, left/right disorientation,
acalculia, limb apraxia (not limb-kinetic), apperceptive
prosopagnosia, agraphia, homonymous visual field
defect, finger agnosia
Core
Neuroimaging
Features:
Supportive
of diagnosis
Predominant occipitoparietal or occipitotemporal atrophy
or hypometabolism or hypoperfusion on MRI, FDG-PET,
or SPECT
Non-posterior
Cortical Features:
All of the following
must be evident
• Relatively spared anterograde memory function
• Relatively spared speech and non-visual language
functions
• Relatively spared executive functions
• Relatively spared behavior and personality
Exclusions: • No afferent visual dysfunction or afferent lesions to
explain symptoms
• No vascular lesions to explain symptoms
• No brain tumor or other mass lesion to explain
symptoms
• No evidence of other causes to explain symptoms
care of patients with PCA, and the experts included behavioral
neurologists, neuropsychologists, psychiatrists, and a neuro-
ophthalmologist/behavioral neurologist (2).
A recent study of the longitudinal cognitive and imaging
profiles from 117 patients with PCA, compared to typical AD,
provided new insights into the PCA presentation and course
within a tertiary dementia center in the United Kingdom and
two other centers in Spain and the United States (7). A recent
multicenter genetic study with just over 300 patients with
PCA from 11 centers worldwide demonstrates how important
collaborative efforts are in generating larger cohorts to better
understand PCA and similar syndromes (8). Nonetheless,
knowledge about the PCA syndrome continues to rely on
patients from large tertiary care centers with extensive research
programs that focus on PCA and/or atypical presentations of AD
(i.e., non-amnestic clinical phenotypes of AD, for instance) or
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small case series of patients. Minimal data exist regarding the
presentation of PCA to the neuro-ophthalmologist, other than
single case reports or small series of PCA patients (previously
referred to as the visual variant of AD) presenting to the neuro-
ophthalmologist with homonymous visual field abnormalities on
threshold perimetry (9, 10).
The utility of studying atypical presentations of AD should not
be underestimated given that atypical AD represents∼25% of the
more than 5 million people living with AD in the United States
(11). Arguably, the study of focal cortical presentations could
contribute to our understanding of disease “spread” in the central
nervous system and help clarify relationships between clinical
manifestations and the interaction of amyloid and tau pathology.
Given this background, we aimed to describe the clinical
presentation of PCA to neuro-ophthalmologists using patient
data collected across multiple institutions and community
practices by a secure, online data registry, and compare findings
to published studies of PCA and to survey data from the
ISTAART Atypical AD PIA cognitive experts.
METHODS
After institutional review board approval, an introductory letter,
and a link to an online, chart review, clinical data survey
was emailed to volunteers from NANOSnet (North American
Neuro-Ophthalmology Society email Listserv) members. The
survey was designed following a literature review to identify
the salient signs and symptoms previously reported for the
presentation of PCA, and participating neuro-ophthalmologists
were instructed to gather patient data via retrospective chart
reviews. The patient data were captured using the REDCap
platform (Research Electronic Data Capture), which is a secure
web application that is compliant with Health Insurance
Portability and Accountability Act, 21CFR part 11, FISMA (low,
moderate, high), and international ethical standards. Posterior
cortical atrophy was defined using the criteria of Tang-Wai
et al. (12), because the survey was developed prior to the
publication of the 2017 research criteria. Variables collected
included certain patient identifiers to prevent duplicate entries,
demographics, presenting and pastmedical histories, evaluations,
and treatments. A list of 18 symptoms (Table 2) was presented to
the physician respondent to indicate the presence of symptoms
at presentation, later in the disease course, never developed, or
unsure. For some symptoms, lay terminology was used. For
others, medical terms were used for the sake of brevity, yet
still interpreted as patient-reported symptoms, for example,
simultanagnosia or apperceptive agnosia. Similarly, for signs
on initial examination, a list was presented for physician
respondents to indicate the presence at presentation, later in
the disease course, never developed, or unsure. Branching logic
helped determine additional details, for example, which color
plate test was used. Data regarding diagnostic testing utilized,
treatment, and subjective assessment of treatment outcomes
were also collected. All sections included an “other” choice with
the opportunity to provide written responses using free text.
All fields were optional to account for missing clinical data.
TABLE 2 | Survey questions regarding initial symptoms at presentation (for survey
questions regarding signs, see manuscript and Figure 1).
With what symptoms did your patient initially present?
1. Blurry vision
2. Difficulty reading
3. Difficulty with depth perception
4. Environmental disorientation
5. Visual hallucinations
6. Alexia
7. Apperceptive visual agnosia
8. Dressing apraxia
9. Limb apraxia
10. Memory difficulty
11. Prosopagnosia
12. Acalculia
13. Agraphia
14. Left/right disorientation
15. Finger agnosia
16. Anomia
17. Parkinsonism
18. Constructional dyspraxia
19. Other (please specify or describe above)
Survey responses were tabulated. Bivariate correlation analysis
was performed to evaluate associations with age.
RESULTS
A total of 12 neuro-ophthalmologists from 11 institutions and
community practices within the United States completed surveys
for 38 patients. The last survey data were collected in 2017, and
more than 97% of survey data were completed within the first 12
months between 2015 and 2016. Physicians were board-certified
ophthalmologists (five) or neurologists (six) with subspecialty
training in neuro-ophthalmology. The patient cohort was 74%
female with a mean age of 67.8 ± 9.70 years and a median age
of 69 years with a range of 45–81 years. Mean and median age
for men was 69.6 ± 9.2 years and 71 years, respectively (range,
48–80 years), and mean and median age for women was 67.1 ±
7.5 years and 64 years, respectively (range, 52–81 years). Twenty-
one percent of patients reported a history of traumatic brain
injury (TBI), and 19% reported a family history of dementia of
the AD type.
Symptoms
The frequency of symptoms at presentation is noted as
percentages in Figure 1. The numerator consists of items marked
as “yes, on presentation,” and the denominator includes those
marked as “no, but developed later in the course” plus “no,
never developed” plus “no, not sure if developed later.” Responses
that were “not sure, but did have later in the course” and “not
sure” were not included in the denominator. This method was
applied in order to report the symptoms that were definitively
determined to be present or not at initial presentation and for
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FIGURE 1 | Reported symptoms (Top) and signs (Bottom) on presentation. Symptoms and signs are reported as a percentage of patients with PCA determined to
have the symptom at initial presentation to the neuro-ophthalmologist.
most symptoms; none to four patients were excluded from the
denominator. Exceptions included apperceptive visual agnosia
(11 uncertain), finger agnosia (6 uncertain), and constructional
dyspraxia (5 uncertain). The most frequent symptom reported by
patients at presentation was “difficulty reading,” which included
91% of patient cases. Memory difficulty was reported by 77% of
patients, and environmental disorientation was noted by 68%,
whereas 65% reported symptoms consistent with constructional
dyspraxia, 63% with difficulty with depth perception, 52% with
agraphia/dysgraphia, and 50% with apperceptive visual agnosia.
Symptoms reported at presentation by fewer than 50% of patients
included blurry vision (48%), anomia (45%), prosopagnosia
Frontiers in Neurology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 358
Olds et al. PCA: Neuro-Ophthalmology Registry
FIGURE 2 | Types of visual field defects in patients with PCA at presentation to the neuro-ophthalmologist.
(38%), dressing apraxia (35%), acalculia (25%), limb apraxia
(20%), left/right disorientation (19%), finger agnosia (12%), and
visual hallucinations (11%). Parkinsonism was listed on the
survey as a “symptom” with the intent to allow the respondents
to interpret symptomatic complaints stemming from resting
tremor, bradykinesia, rigidity, and postural instability as
parkinsonian symptoms, and 10% of patients had symptoms of
parkinsonian traits at presentation. Other symptoms written in
by respondents included photophobia (four patients). Alexia, or
marked loss or loss of ability to read, was a presenting symptom in
74% of patients; a second survey question asked whether patients
complained simply of “reading difficulty,” and 91% of patients
reported such.
Signs
The frequency of signs reported at presentation is noted as
percentages in Figure 2. For the same reasons as noted for report
of symptoms, the numerator consists of items marked as “yes,
on presentation,” and the denominator includes those marked as
“no, but developed later in the course” plus “no, never developed”
plus “no, not sure if developed later.” Responses that included
“not sure, but did have later in the course” and “not sure”
were not included in the denominator. Of the initial findings
on examination, threshold perimetric visual field defects were
present in 89% of the patients, with 62% revealing homonymous
defects (Figure 2). The majority of homonymous defects were
left-sided. Generalized constriction, which is a pattern revealing
decreased peripheral vision with sparing of the central portions
of the visual field, was present in 9% of the patients. Three
patients had normal studies, and only two patients were unable
to perform visual field testing reliably, as determined by the
neuro-ophthalmologist. Color plate testing was abnormal in 88%
of patients, and just over 50% of patients were tested with
the Hardy–Rand–Rittler (HRR) pseudoisochromatic test plates
and the remainder with Ishihara color plates. Just over half of
the patients (52%) were unable to see the control color plate,
and this was more commonly reported for those testing with
HRR plates. Decreased Titmus stereopsis at near was noted in
86% of patients. Decreased visual acuity (i.e., best corrected
visual acuity <20/20 either eye) was present in 60% of patients,
simultanagnosia in 59%, and abnormalities noted on Amsler grid
testing found in 58%. Central vision crowding (defined as better
visual acuity performance with use of single letter compared to
flanked letter testing) was noted in 54%. Optic ataxia was noted
in 37%, oculomotor apraxia in 32%, and visual neglect in 29%
of patients on initial examination. Uncertainty regarding the
presence of signs at presentation was greater than that noted
for symptoms, and this included 20 of 38 patients for crowding,
12 of 38 for optic ataxia, 12 of 38 for Titmus stereopsis, 11 of
38 for oculomotor apraxia, 5 of 38 for visual neglect, 5 of 38
for color plate testing, and 6 of 38 for simultanagnosia. The
authors note that the uncertainty of these signs at presentation
was due to lack of specific testing or documentation of testing at
initial presentation.
Evaluation
Thirty-five of 38 patients were reported as having magnetic
resonance (MR) imaging of the brain, and two had computed
tomography (CT) brain imaging. Of the reported findings
on neuroimaging, generalized atrophy was most commonly
found, and only one imaging report specifically noted the
predominance of PCA. However, review of the brain imaging
revealed that 34 of 38 CT brain scans by MR and CT had
posterior atrophy (occipitoparietal, parietal–occipital–temporal,
or both with or without mesiotemporal atrophy). Five were
normal. A total of 12 patients underwent fluorodeoxyglucose
(FDG) positron emission tomography (PET) imaging, and
occipitoparietal hypometabolism was described in 50% (6/12),
occipitoparietotemporal hypometabolism in 33% (4/12), and
mesiotemporal hypometabolism in 17% (2/12). Cerebrospinal
fluid (CSF) was collected on three patients, and two had
testing for phosphorylated tau (p-tau) and amyloid beta
42 (Abeta42) levels, both of which are valid and sensitive
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markers for AD pathology. An abnormal CSF ratio of p-
tau/Abeta42, in a manner consistent with AD pathology,
was noted for both patients. One had slightly elevated
CSF protein.
Treatment
Twenty patients received treatment with medications that
included one or more of the following: donepezil, rivastigmine,
galantamine, and memantine. Ten patients were treated with
donepezil (50%) and nine with memantine (45%). Rivastigmine
and galantamine were less commonly used, and six patients
were trialed on two or more of the medications noted. Only
six respondents answered whether there was a response to
medication treatment as determined by subjectivemeasures, and
two of six reported response as unknown, one of six noted
the medication was not tolerated (donepezil), one of six noted
subjective improvement with donepezil, one of six reported
subjective improvement with galantamine and memantine, and
one of six noted no benefit with memantine.
Age Associations
Correlation analyses between age and signs and symptoms
revealed statistically significant (p < 0.05) negative correlations
for limb apraxia (r = −0.47) and left–right disorientation (r
= −0.44). Thus, with older age, patients were less likely at
presentation to have limb apraxia and left–right disorientation,
which represent functions that, in general, localize to the
dominant posterior.
DISCUSSION
This study of the clinical characteristics of patients with
PCA syndrome presenting to the neuro-ophthalmologist was
undertaken as a retrospective chart review by 11 neuro-
ophthalmologists from 11 institutions and community practice-
based clinics. Several important findings deserve highlighting.
In particular, the demographics of this cohort show slight
differences with prior reports. Our cohort had 74% women,
whereas a recent multicenter PCA study by Firth et al. (7) with
117 patients had 61% women. A large, multicenter PCA genetic
risk study, by Schott et al. (8), had 59% women in a cohort
of 302 patients. Given the 3:1 ratio of women to men in our
cohort, it is worthwhile to determine whether women are more
likely to be referred to a neuro-ophthalmologist for unexplained
visual symptoms due to PCA or if a larger sample size would
reveal no differences in gender for PCA presentation to the
neuro-ophthalmologist compared to other cohorts. Average age
at presentation in our cohort was 67.8± 9.70 years with a median
of 69 years, and this represents an older age than in published
reports, which reveal an average age of <65 years. The study
of Schott et al. (8) reported an average age of 58.9 ± 6.9 years,
and 60 ± 8.1 years was the average age in the study of Firth
et al. (7). The age range of 45–81 years in our cohort is wide,
with half of the cohort greater than the median age of 69 years.
The reason for an older age at presentation in this cohort is
unknown. Interestingly, a study by Millington et al. (13) with
10 patients with PCA recruited from a neuro-ophthalmology
clinic in the United Kingdom reported an age range of 53–77
years with a median of 70 years. As with biological sex, age
at presentation to the neuro-ophthalmologist deserves further
investigation to determine if those patients presenting to a neuro-
ophthalmologist are a unique clinical cohort or represent people
with PCA with a greater than average delay in diagnosis.
The prevalence of TBI of 21% in this cohort is low given
that as many as 40% of the general population report a history
of TBI during their lifetime (14). There is controversy as to
whether TBI is a definitive risk factor for AD pathology (14),
and more work is necessary to understand the relationship
between TBI and PCA. Meanwhile, the nature of this study
does not allow further conclusions at this stage. With regard to
family history, the prevalence of dementia or AD in first-degree
relatives of people with PCA is unknown and is infrequently
reported in published cohorts. One longitudinal study of 12
patients from Australia noted only one patient (8%) reported
a family history of dementia (15), whereas our cohort had
more than double that prevalence. Until larger cohort studies
collect and report family history, these data are challenging
to interpret.
Among presenting symptoms, difficulty reading was the
greatest concern by patients on presentation to the neuro-
ophthalmologist and was reported by 91%. The published
survey of cognitive experts noted that alexia is thought not
to be as common at presentation, with most experts rating
its frequency as either “rare” (0–25%) or “common” (25–
75%) (2). Methodological differences (opinion survey vs. chart
review), physician specialty (cognitive specialist vs. neuro-
ophthalmologist) influencing history reporting and/or gathering,
or a combination of these factors, could have contributed to these
differences. Nonetheless, it is possible that patients with difficulty
reading are more likely to present to the neuro-ophthalmologist
than a cognitive specialist. One study from China that evaluated
reading differences between patients with PCA and patients
with non-PCA early-onset AD (EOAD) reported that reading
issues could differentiate PCA from EOAD, and characteristic
issues included missing words (94%), getting lost on the page
(86%), and getting lost from one line to the next (67%) (16),
which is similar to English language reports, but the problems
encountered while reading were not assessed during the clinical
consultations of patients in our study.
Memory complaints were commonly reported in our cohort
(77%), while the survey of cognitive experts indicates that
the frequency of anterograde memory deficit is similar to the
frequency of alexia, either “rare” (0–25%) or “common” (25–
75%) (2). The differences could be contributed to the older age
of our cohort, but there was no statistically significant correlation
between age and the presence of a memory complaint in our
cohort. Given the differences between methodologies (survey
vs. chart review) and the lack of standardized collection of
data, these differences might not be significant. Limb apraxia
and left–right disorientation were negatively correlated with age
in our cohort, and longitudinal studies will be necessary to
know how age influences the sign and symptom profile of PCA
syndrome at presentation and whether a specific atrophy or
dysfunctional network pattern can be recognized as age related.
It is interesting to note that many patients with PCA report
symptoms ofmemory dysfunction even when higher-order visual
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processing deficits are likely to blame for their concerns about
memory. For instance, a patient with PCA (not within this
cohort) presented with complaints that she had difficulty finding
her hamper in her bedroom because she “. . . could not remember
where it was.” Given that this patient had moderate to severe
simultanagnosia and higher-order visual dysfunction with only
mild memory dysfunction, this complaint was more likely due
to an inability to “see” the hamper due to loss of simultaneous
perception rather than an inability to recall “where” the hamper
was in the bedroom. A recent study of 12 patients with PCA
and simultanagnosia revealed that slowed visual processing
speed, and not visual short-term memory capacity, explains
simultanagnosia (17), and interestingly, atrophy of white matter,
specifically the superior longitudinal fasciculus and not gray
matter, was linked to slowed processing speed.
In regard to signs on examination, visual field defects
(89%), color plate testing abnormalities (88%), and stereovision
impairment (86%) were very common. Visual field defects were
reported in the previously published expert survey as either
“rare” (0–25%) or “common” (25–75%) at presentation (2).
This discrepancy is most likely due to methods of clinical
assessment, particularly with regard to visual field testing
because threshold perimetry is a routine tool employed in the
evaluation of patients presenting to the neuro-ophthalmologist,
and threshold perimetry is a sensitive measure of diminished
stimulus detection as opposed to confrontational visual field
testing with finger counting. In support of this is the finding
of a similarly high prevalence of visual field defects when
threshold perimetry was used in a smaller cohort of PCA
patients who presented from behavioral neurology clinics (9).
Homonymous defects in our cohort accounted for 62% of visual
field defects, and 83% were left-sided. This pattern is consistent
with prior studies (10). A recent study of patients with PCA
and homonymous visual field defects found that the hemifield
defect is associated with contralateral occipital atrophy, as well as
contralateral hippocampal and parahippocampal gyrus atrophy
and diminished contralateral posterior white matter integrity,
specifically the optic radiations contralateral to the field of vision
loss (13). Changes in white matter integrity in PCA deserve more
attention given these recent findings by Millington et al. (13) and
the findings Neitzel et al. (17) regarding the superior longitudinal
fascicle and simultanagnosia. It is also noteworthy that only 2 of
38 patients with PCA had unreliable visual field testing. Future
investigation regarding the value of threshold visual perimetry as
a unique diagnostic biomarker of the PCA syndrome is indicated.
Pseudoisochromatic color vision testing abnormalities
were very common and could reflect central achromatopsia,
simultanagnosia, or both. Since simultanagnosia was reported
in just under 60% of patients, whereas abnormal color plate
testing was noted in 88% of patients, then central achromatopsia
as a contributing factor is possible, particularly because the
presence of simultanagnosia was not significantly correlated to
color plate testing abnormalities in this cohort. However, 13 of
25 patients tested with pseudoisochromatic color plates were
unable to see the control plate, which should be identifiable
to those with achromatopsia but without simultanagnosia.
Further investigation using color vision tests that do not rely
on identification of an embedded figure will be necessary to
better understand the frequency of central achromatopsia at
presentation with PCA and the utility of central achromatopsia
as a clinical marker of PCA. Impaired stereopsis was also
common in this PCA cohort, and this could be due to a variety
of different causes, but data regarding monocular visual acuities
and history of amblyopia were not collected. The high prevalence
of impairment, nonetheless, deserves further investigation in
order to determine whether the underlying cause for this sign
stems from poor central fusional capacity.
Central vision crowding was detected in more than half of the
20 patients whose crowding status at presentation was known,
and visual crowding is a well-recognized phenomenon of the
PCA syndrome. In the neuro-ophthalmology clinic, evaluation
for crowding is typically assessed by comparing visual acuity
using letters flanked by other letters to visual acuity using letters
that are non-flanked (or isolated). As noted, however, a history
of amblyopia was not surveyed, and a recent population-based
study found a prevalence of amblyopia is∼7% in people between
55 and 65 years old (18). Recent work by de Best et al. (19) sheds
light on the potential mechanism of central vision crowding in
PCA. Investigators found that population receptive fields (pRF)
in V1 (striate cortex) and V4 (including lingual and fusiform
regions) are larger in foveal regions and smaller in peripheral
regions than in healthy controls. The authors theorized that
because neurons dedicated to foveal vision suffer from an
impaired ability to properly process a stimulus that is crowded by
other stimuli when their pRF enlarges, central vision crowding
follows. With shrinking of the pRF for peripheral (non-foveal)
neurons, local stimulus features are processed at the expense of
global features, and the result is simultanagnosia. These findings
and theory deserve further exploration and have implications
for understanding crowding in other disorders. Reduced visual
acuity was more common (60%) in our cohort than the survey
by experts, and again, this is likely due to the methodology
(survey of impressions vs. chart review), subspecialty assessment
(cognitive specialists vs. neuro-ophthalmologists), or older age
of patients. Until further investigations occur, the reasons will
remain unknown.
Brain imaging was most commonly reported as “generalized
atrophy,” and it behooves the clinician to review the imaging
for signs of posterior greater than anterior atrophy and consider
PET-FDG imaging, as findings indicated posterior predominant
atrophy in nearly all cases. In regard to treatment, although
medications are commonly prescribed, there are no known
effective pharmaceutical therapies for the PCA syndrome.
The major limitation of this study is that it is a retrospective
chart review of clinical data that were not collected using a
standardized assessment protocol.
CONCLUSION
The presentation of PCA to the neuro-ophthalmologist in
this cohort is slightly different than the presentation reported
in published cohorts and reported by cognitive specialists.
Symptoms and signs at presentation are comparable, but patients
presenting to the neuro-ophthalmologist with PCA are more
likely to be older than 65 years, female, and with concerns about
reading. Furthermore, visual field defects, pseudoisochromatic
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color vision test abnormalities, and abnormal stereopsis were
very common, and visual field tests were performed reliably
by nearly all patients. Consistent with other investigations of
PCA, left-sided, homonymous visual field defects were the most
common field abnormality. The frequency of these abnormal
signs likely reflects the unique evaluation performed within a
neuro-ophthalmology clinic and reveals potential to be useful
markers of the PCA syndrome.
Neuro-ophthalmologists play a critical role in diagnosing PCA
and can contribute to a better understanding of the syndrome.
Future investigations of PCA should focus on longitudinal,
standardized data collection from multiple institutions and
centers, with involvement of a wide spectrum of subspecialists,
including those practicing in the community. Early recognition
and a better understanding of progression of the PCA syndrome
will benefit patients, families, and care partners and contribute
to our understanding of disease mechanisms and development of
new therapies.
RESOURCE IDENTIFICATION INITIATIVE
REDCap, RRID:SCR_003445.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation, to any
qualified researcher.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the OHSU Institutional Review Board. Written
informed consent for participation was not required for this
study in accordance with the national legislation and the
institutional requirements.
AUTHOR CONTRIBUTIONS
JO and WH contributed to the conception or design of the
work and oversaw the statistical analysis. VP, JO, and WH
analyzed and interpreted the data, and wrote and revised the
manuscript. JW, JF, LA, MM, RE, WC, AL, BF, RT, DK,
and JC contributed to the acquisition of data for the work.
All authors contributed to manuscript read and approved the
submitted version.
FUNDING
WH was supported in part by Unrestricted Grant from Research
to Prevent Blindness and P30 EY010572.
ACKNOWLEDGMENTS
The authors wish to thank Dr. Marilyn Kay for her contribution
and Jerri Lusk for her help in manuscript preparation.
REFERENCES
1. Crutch SJ, Lehmann M, Schott JM, Rabinovici GD,
Rossor MN, Fox NC. Posterior cortical atrophy. Lancet
Neurol. (2012) 11:170–8. doi: 10.1016/S1474-4422(11)
70289-7
2. Crutch SJ, Schott JM, Rabinovici GD, Murray M, Snowden JS, van
der Flier WM, et al. Consensus classification of posterior cortical
atrophy. Alzheimers Dement. (2017) 13:870–84. doi: 10.1016/j.jalz.2017.
01.014
3. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol.
(1988) 45:789–93.
4. Kujovic M, Malikovic A, Jochum S, Margittai Z, Lange-Asschenfeldt C,
Supprian T. Longitudinal progression of posterior cortical atrophy over
11 years: relationship between lesion topology and clinical deficits. J
Clin Exp Neuropsychol. (2019) 41:875–80. doi: 10.1080/13803395.2019.1
638345
5. Javaid MK, Forestier-Zhang L, Watts L, Turner A, Ponte C, Teare H,
et al. The RUDY study platform - a novel approach to patient driven
research in rare musculoskeletal diseases. Orphanet J Rare Dis. (2016) 11:150.
doi: 10.1186/s13023-016-0528-6
6. Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S,
Rabinovici GD, et al. Clinical syndromes associated with posterior
atrophy: early age at onset AD spectrum. Neurology. (2009) 73:1571–8.
doi: 10.1212/WNL.0b013e3181c0d427
7. Firth NC, Primativo S, Marinescu RV, Shakespeare TJ, Suarez-Gonzalez
A, Lehmann M, et al. Longitudinal neuroanatomical and cognitive
progression of posterior cortical atrophy. Brain. (2019) 142:2082–95.
doi: 10.1093/brain/awz136
8. Schott JM, Crutch SJ, Carrasquillo MM, Uphill J, Shakespeare TJ,
Ryan NS, et al. Genetic risk factors for the posterior cortical atrophy
variant of Alzheimer’s disease. Alzheimers Dement. (2016) 12:862–71.
doi: 10.1016/j.jalz.2016.01.010
9. Lee AG, Martin CO. Neuro-ophthalmic findings in the
visual variant of Alzheimer’s disease. Ophthalmology. (2004)
111:376–80; discussion: 380–71. doi: 10.1016/S0161-6420(03)
00732-2
10. Pelak VS, Smyth SF, Boyer PJ, Filley CM. Computerized
visual field defects in posterior cortical atrophy. Neurology.
(2011) 77:2119–22. doi: 10.1212/WNL.0b013e31823
e9f2a
11. Qiu Y, Jacobs DM, Messer K, Salmon DP, Feldman HH.
Cognitive heterogeneity in probable Alzheimer disease: clinical
and neuropathologic features. Neurology. (2019) 93:e778–90.
doi: 10.1212/WNL.0000000000007967
12. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE,
Crook R, et al. Clinical, genetic, and neuropathologic characteristics
of posterior cortical atrophy. Neurology. (2004) 63:1168–74.
doi: 10.1212/01.wnl.0000140289.18472.15
13. Millington RS, James-Galton M, Maia Da Silva MN, Plant GT, Bridge
H. Lateralized occipital degeneration in posterior cortical atrophy
predicts visual field deficits. Neuroimage Clin. (2017) 14:242–9.
doi: 10.1016/j.nicl.2017.01.012
14. Weiner MW, Crane PK, Montine TJ, Bennett DA, Veitch DP.
Traumatic brain injury may not increase the risk of Alzheimer
disease. Neurology. (2017) 89:1923–5. doi: 10.1212/WNL.00000000000
04608
15. Panegyres PK, Goh J, McCarthy M, Campbell AI. The nature
and natural history of posterior cortical atrophy syndrome: a
variant of early-onset Alzheimer disease. Alzheimer Dis Assoc
Disord. (2017) 31:295–306. doi: 10.1097/WAD.0000000000
000207
Frontiers in Neurology | www.frontiersin.org 8 June 2020 | Volume 11 | Article 358
Olds et al. PCA: Neuro-Ophthalmology Registry
16. Li J, Wu W, Tang Y, Zhou A, Wang F, Xing Y, et al. Differentiation
of neuropsychological features between posterior cortical atrophy
and early onset Alzheimer’s disease. BMC Neurol. (2018) 18:65.
doi: 10.1186/s12883-018-1068-6
17. Neitzel J, Ortner M, Haupt M, Redel P, Grimmer T, Yakushev I, et al.
Neuro-cognitive mechanisms of simultanagnosia in patients with posterior
cortical atrophy. Brain. (2016) 139(Pt 12):3267–80. doi: 10.1093/brain/a
ww235
18. Faghihi M, Hashemi H, Nabovati P, Saatchi M, Yekta A, Rafati S, et al.
The prevalence of amblyopia and its determinants in a population-
based study. Strabismus. (2017) 25:176–83. doi: 10.1080/09273972.2017.13
91849
19. de Best PB, Raz N, Guy N, Ben-Hur T, Dumoulin SO, Pertzov Y, et al.
Role of population receptive field size in complex visual dysfunctions:
a posterior cortical atrophy model. JAMA Neurol. (2019) 76:1391–6.
doi: 10.1001/jamaneurol.2019.2447
Conflict of Interest: The views expressed are those of the author and do not reflect
the official policy or position of the US Air Force, Department of Defense, Defense
Health Agency, or the US Government.
The authors declare that the research was conducted in the absence of any
commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Olds, Hills, Warner, Falardeau, Alasantro, Moster, Egan,
Cornblath, Lee, Frishberg, Turbin, Katz, Charley and Pelak. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neurology | www.frontiersin.org 9 June 2020 | Volume 11 | Article 358
